Medpace Holdings, INC 10-Q quarterly reports

Medpace Holdings, Inc. announced robust financial performance for the second quarter of 2026, with significant year-over-year growth in revenue and net income.

Medpace Holdings reports strong Q1 2026 results with significant revenue growth and improved net income, driven by key therapeutic areas.

Medpace Holdings, Inc. announced robust financial results for the third quarter and nine months ended September 30, 2025, driven by significant revenue and net new business award increases.

Medpace Holdings, Inc. announced a significant increase in second-quarter revenue and net income, driven by growth in key therapeutic areas, while executing substantial share repurchases.

Medpace Holdings, Inc. announces increased revenue and net income for Q1 2025, along with an expansion of its stock repurchase program.

Medpace Holdings, Inc. announced a robust third quarter for 2024, with revenue increasing by 8.3% compared to the same period last year.

Medpace Holdings, Inc. announced a significant increase in revenue and backlog for the second quarter of 2024, driven by growth across multiple therapeutic areas.

Medpace Holdings, Inc. announced a robust first quarter of 2024, with revenue increasing by 17.7% year-over-year.